Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial ...

Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it | ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

“The results of our analysis showed that overall, patients with SCLC who survived to receive 3L treatment are a select group ...

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...

Camrelizumab plus famitinib significantly improved PFS and OS compared to platinum-based chemotherapy in recurrent/metastatic cervical cancer. The trial reported a median PFS of 11.1 months for the ...

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...